From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 mainprotease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 mainprotease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoVmainprotease (Mpro) .
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 mainprotease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
Ulinastatin (Uristatin) is a trypsin and serine protease inhibitor. Ulinastatin is the main protein binding inhibitor of various trypsin, chymotrypsin, and various pancreatic proteases. Ulinastatin shows neuroprotective, anti-inflammatory, anti-apoptotic, anti-oxidant effects .
Bofutrelvir (FB2001) is a SARS-CoV-2 mainproteaseM pro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
Olgotrelvir (STI-1558) sodium is an orally active dual inhibitor of coronavirus mainprotease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir sodium is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir sodium can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
X77 is a potent non-covalent inhibitor of the mainprotease of SARS-CoV-2 (SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM .
BOC-(1R,3S)-3-aminocyclopentane carboxylic acid ((1S,3S)-3-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid) is a conformationally constrained peptide building block and a key component of SARS-CoV-2mainprotease (Mpro) inhibitors. When incorporated into macrocyclic peptides, BOC-(1R,3S)-3-aminocyclopentane carboxylic acid not only helps generate high-affinity Mpro inhibitors by preorganizing the secondary structure of peptides, but also exerts sequence-dependent functional inhibition on the hydrolytic activity of Mpro. BOC-(1R,3S)-3-aminocyclopentane carboxylic is widely used in COVID-19-related research .
Tirilazad (U 74006F free base) is a neuroprotective agent. Tirilazad can also bind tightly to the mainprotease of the COVID-19 virus and exert anti-SARS-CoV-2 activity. Tirilazad scavenges hydroxyl and lipid peroxyl free radicals and maintains the levels of endogenous antioxidants. Tirilazad reduces cerebral infarct volume and improves neurobehavioral scores in animal models of focal ischemia. Tirilazad can be used in research related to ischemic stroke and subarachnoid hemorrhage .
Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus mainprotease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells .
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 mainprotease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
(Rac)-X77?is a racemate of X77. X77 is a potent non-covalent inhibitor of the mainprotease of SARS-CoV-2 (SARS-CoV-2 M pro) . X77 binds to SARS-CoV-2 M pro with a Kd value of 0.057 μM .
Tectoquinone (Standard) is the analytical standard of Tectoquinone. This product is intended for research and analytical applications. Tectoquinone (2-Methylanthraquinone) is a SARSCoV-2 mainprotease inhibitor against COVID-19. Tectoquinone exhibits strong mosquito larvicidal activity with the LC50 values of 3.3 and 5.4 μg/ml against A. aegypti and A. albopictus in 24 h, respectively .
Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoV mainprotease (Mpro) .
NZ-804 is an orally active inhibitor for SARS-CoV-2 mainprotease Mpro with an IC50 of 8.9 nM. NZ-804 inhibits the SARS-CoV-2 replication in HeLa-hACE2 cell with an EC50 of 14 nM. NZ-804 exhibits board-spectrum antiviral activity aganst multiple CoVs. NZ-804 diminishes virus replication in mouse and hamster model .
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 mainprotease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
SPR38 is a potent SARS-CoV-2 mainprotease inhibitor, with a Ki of 0.260 μM. SPR38 also inhibits hCatL and hCatB, with Ki values of 1.92 μM and 11.1 μM, respectively .
SARS-CoV-2 mainprotease is a mainprotease (Mpro) of SARS-CoV-2, which plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19 .
TPG-20A is a SARS-CoV-2mainprotease inhibitor with an IC50 of 27.8 nM. TPG-20A also inhibits MERS-CoV mainprotease. TPG-20A can be used for the research of infection, such as SARS-CoV-2 .
MC12 is a thiazole-based derivative and a SARS-CoV-2 mainprotease inhibitor (IC50: 77.7 nM). MC12 exhibits inhibitory effects on both SARS-CoV and SARS-CoV-2 mainproteases, with low cytotoxicity and good stability. MC12 can be used in the research of anti-COVID-19 drugs .
Leupeptin (hemisulfate) (Standard) is the analytical standard of Leupeptin (hemisulfate). This product is intended for research and analytical applications. Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity[1][2][3].
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2mainprotease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
AS-0017445 is an inhibitor targeting the mainprotease of both the current coronavirus and the virus that caused the Middle East Respiratory Syndrome (MERS) outbreak. AS-0017445 inhibits the viral protein processing in host cells and thus prevents viral replication .
PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs) .
Euptox A (9-Oxo-10, 11-dehydroageraphorone), a cadenine sesquiterpene, is the main toxin that can be isolated from Eupatorium adenophorum. Euptox A induces apoptosis by improving the gene expression level of apoptotic proteases such as caspase-10 in HeLa cells .
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 mainprotease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the mainprotease (M pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 mainprotease (M pro) inhibitor (IC50=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus .
Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 mainprotease (M pro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections .
Cathepsin K inhibitor 2 is a potent inhibitor of cathepsin K. Cathepsin K, Cat K is a cysteine protease expressed under the control of CTSK gene and closely related to osteoporosis, whose main function is to hydrolyze collagen. Cathepsin K inhibitor 2 has the potential for the research of osteoarthfitis (extracted from patent WO2021147882A1, compound 78) .
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (mainprotease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity). Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].
ML2006a4 is an orally active inhibitor for SARS-CoV-2 mainprotease (M pro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level
HP211206 is a SARS-CoV-2 mainprotease (M pro) PROTAC degrader. HP211206 effectively degrades SARS-CoV-2 M pro and its drug-resistant mutants. HP211206 has an IC50 of 181.9 nM and a DC50 of 621 nM for M pro. HP211206 has antiviral activity. (Pink: H117 (HY-170599); Black: linker (HY-B0236); Blue: E3 ligase ligand (HY-41547)) .
SARS-CoV-2 Mpro-IN-21 (compound A8) is a potent SARS-CoV-2 and OVID-19 MainProtease M Pro inhibitor. SARS-CoV-2 Mpro-IN-21 shows excellent antioxidant activity in DPPH assay with an IC50 of 0.36 mg/mL. SARS-CoV-2 Mpro-IN-21 also exhibits better antibacterial potency against Klebsiella with an IC50 of 1.19 mg/mL .
SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2 mainprotease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research .
SARS-CoV-2-IN-112 (Compound 6f) is an orally active and non-peptidic SARS-CoV-2 mainprotease inhibitor with an IC50 of 6.48 μM. SARS-CoV-2-IN-11 has potent antiviral activity with low cytotoxicity against WI-38 cells (IC50: 53.81 μM). SARS-CoV-2-IN-112 can be used for coronaviruses COVID-19 research .
SARS-CoV-2 Mpro-IN-42 (compound C5) is a potent SARS-CoV-2 Mpro inhibitor with an IC50 of 33.6 nM. SARS-CoV-2 Mpro-IN-42 can be used in the study of SARS-CoV-2 .
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the mainprotease of SARS-CoV-2 (Mpro) .
FL-166 is a SARS coronavirus mainprotease (Mpro) inhibitor (Ki: 40 nM). FL-166 exerts its inhibitory effect by targeting a cluster of serine residues near the active site of the protease. FL-166 can be used in the study of SARS-CoV .
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2mainprotease (M pro), which can be used in the research of anti-novel coronavirus drugs .
SARS-CoV-2 Mpro-IN-20 (compound MPI100) is a SARS-CoV-2mainprotease inhibitor. SARS-CoV-2 Mpro-IN-20 shows antiviral activity with the EC50 of 3.4 μM .
SPR41 is a potent SARS-CoV-2 mainprotease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity .
SPR39 is a potent SARS-CoV-2 mainprotease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity .
H117 is a PROTAC target protein ligand that can be used to synthesize PROTAC HP211206 (HY-170598). H117 has competitive binding and inhibition ability on SARS-CoV-2 mainprotease (M pro) with an IC50 of 151.3 nM .
SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 mainprotease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research .
UCI-1 is a SARS-CoV-2 mainprotease (M pro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M pro. UCI-1 can be used in the study of anti-COVID-19 drugs .
CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the mainprotease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM) .
SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC50 value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 mainprotease (M pro) and a non-covalent inhibitor of papain (PL pro) .
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule inhibitor of SARS-CoV-2 that targets the mainprotease (Mpro) of the coronavirus. SARS-CoV-2-IN-59 has a strong interaction with residues on Mpro (Met 165, Gln 166, Met 165, His 41, Gln 189) .
AB-343 is a selective covalent inhibitor of SARS-CoV-2 Mpro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit the mainproteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
SARS-CoV-2 Mpro-IN-48 is a potent SARS-CoV-2mainprotease inhibitor with an IC50 of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19 .
SARS-CoV-2 Mpro-IN-39 (Compound 9d) is an inhibitor of the mainprotease (Mpro) of SARS-CoV-2, with an IC50 value of 5.94 µM, an EC50 value of 9.33 µM for inhibiting the replication of SARS-CoV-2 in Vero cells, and a cytotoxicity CC50 value of 289.63 µM. SARS-CoV-2 Mpro-IN-39 can be used in the research of the anti-COVID-19 field .
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The mainprotease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
MAT-POS-e194df51-1 is an orally active, non-covalent and non-peptide SARS-CoV-2mainprotease (M pro) inhibitor with an IC50 value of 37nM. MAT-POS-e194df51-1 is cytotoxic with EC50 values of 64 nM and 126 nM in A549-ACE2-TMPRSS2 cells and HeLa -ACE2 cells, respectively .
SARS-CoV-2 Mpro-IN-5 is a dual Inhibitor of MainProtease (M Pro) and Cathepsin L (CatL), with IC50s of 1800 nM and 145 nM respectively. SARS-CoV-2 Mpro-IN-5 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-5 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 14.7 nM .
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of MainProtease (M Pro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM .
SARS-CoV-2 Mpro-IN-29 (Compound 7) is an inhibitor of the SARS-CoV-2 mainprotease (Mpro) with an IC50 of 310 nM and an EC50 of 0.5 μM in Vero cells. SARS-CoV-2 Mpro-IN-29 binds to the active site of Mpro, blocking the cleavage of viral polyproteins, showing significant antiviral activity and enhanced metabolic function. SARS-CoV-2 Mpro-IN-29 holds potential for research on SARS-CoV-2 antiviral agents .
SARS-CoV-2 Mpro-IN-54 is a SARS-CoV-2 mainprotease (Mpro) inhibitor with an IC50 of 12.5 nM against SARS-CoV-2 Mpro. SARS-CoV-2 Mpro-IN-54 functionally inhibits SARS-CoV-2 mainprotease activity. SARS-CoV-2 Mpro-IN-54 can be used for the research of COVID-19 .
TLP-3, Temporin L (HY-P2523) analogue, is a SARS-CoV-2mainprotease (Mpro) inhibitor with an IC50 of 7.0 μM. TLP-3 inhibits protease activity through stabilizing hydrogen bonding and hydrophobic interactions with key enzyme residues. TLP-3 can be used for the research of ARS-CoV‑2 infection .
Artecanin is a SARS-CoV-2 mainprotease (M pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M pro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with M pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .
SARS-CoV-2 Mpro-IN-57 is an irreversible SARS-CoV-2mainprotease inhibitor with an IC50 of 0.41 μM and a Kd of 247.37 nM. SARS-CoV-2 Mpro-IN-57 forms a covalent bond with the key amino acid residue Cys145 in SARS-CoV-2 mainprotease via its -CN group. SARS-CoV-2 Mpro-IN-57 can be used for the research of COVID-19 .
VPC285785 is an orally active SARS-CoV-2mainprotease inhibitor with an IC50 of 0.8 μM and a Kd of 2.7 μM. VPC285785 functionally inhibits the viral mainprotease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections .
SIMR-2418 is an effective inhibitor of the mainprotease (M pro) of SARS-CoV-2, with an IC50 value of 20.7 μM. SIMR-2418 can be used for research on SARS-CoV-2 virus infection .
UAWJ-247 is a potent and reversible SARS-CoV-2mainprotease (Mpro) inhibitor with an IC50 of 0.042 μM and a Ki of 0.035 μM. UAWJ-247 can be used for the research of covid-19 .
UAWJ246 is a covalent reversible inhibitor of the SARS-CoV-2mainprotease (Mpro), with an IC50 of 0.045 μM and a Ki of 0.036 μM. UAWJ246 exhibits potent antiviral activity by inhibiting SARS-CoV-2 viral replication and shows low cytotoxicity. UAWJ246 can be used in research related to SARS-CoV-2 infection, such as studies on COVID-19 [1][2].
UAWJ248 is a SARS-CoV-2 mainprotease (M pro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection .
PROTAC SARS-CoV-2 Mpro degrader-7 is a SARS-CoV-2 mainprotease (Mpro) PROTAC degrader with a DC50 of 0.985 μM. PROTAC SARS-CoV-2 Mpro degrader-7 promotes K48-linked polyubiquitination of SARS-CoV-2 Mpro, leading to proteasome-dependent degradation via the ubiquitin-proteasome system.PROTAC SARS-CoV-2 Mpro degrader-7 forms a ternary complex with SARS-CoV-2 Mpro and CRBN E3 ubiquitin ligase to enable viral protease ubiquitination.PROTAC SARS-CoV-2 Mpro degrader-7 exhibits a high selectivity index, and induces dose-dependent degradation of SARS-CoV-2 Mpro in stable cells expressing the viral protease.PROTAC SARS-CoV-2 Mpro degrader-7 can be used for the research of COVID-19 .
PROTAC SARS-CoV-2 Mpro degrader-8 is an antiviral PROTAC degrader targeting the SARS-CoV-2mainprotease (Mpro), with weak direct binding affinity to Mpro (Kd=80.5 μM). PROTAC SARS-CoV-2 Mpro degrader-8 exhibits broad-spectrum antiviral activity against SARS-CoV-2 and the human endemic coronavirus HCoV-OC43. It can be used for research on coronavirus infections .
Jun13698 is a SARS-CoV-2mainprotease (M pro) inhibitor with Ki values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant M pro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research .
Mpro/PLPro-IN-2 (Compound 22l) is a non-covalent competitive dual inhibitor of the papain-like protease and mainprotease of SARS-CoV-2, with a Ki of 0.2 μM for the papain-like protease and a Ki of 1.1 μM for the mainprotease . Mpro/PLPro-IN-2 can be used in the research field of anti-SARS-CoV-2 .
PROTAC SARS-CoV-2 Mpro degrader-5 is a SARS-CoV-2 mainprotease (Mpro) PROTAC. PROTAC SARS-CoV-2 Mpro degrader-5 engages CRBN E3 ubiquitin ligase to form a ternary complex with SARS-CoV-2 Mpro, induces K48-linked polyubiquitination of SARS-CoV-2 Mpro, and drives proteasome-dependent turnover of SARS-CoV-2 Mpro with a high selectivity index (CC50/DC50 > 10) in human embryonic kidney cells.PROTAC SARS-CoV-2 Mpro degrader-5 can be used for the research of COVID-19 .
Oberadilol (CID-3047798) is an ACE2 receptor binding agent. Oberadilol binds to the human ACE2 receptor and SARS-CoV proteins (Spike S glycoprotein, protease) with a Kd of 23.18 mM for the SARS-CoV-2 mainprotease .
SARS-CoV-2 Mpro-IN-55 is a SARS-CoV-2 M pro inhibitor with a IC50 value of 7.20 nM. SARS-CoV-2 Mpro-IN-55 shows limited inhibitory activity against SARS-CoV-2. SARS-CoV-2 Mpro-IN-55 can be used in research related to COVID-19 .
(S,R,S)-AHPC-Me-C2-piperazine is an E3 ligase ligand-linker conjugate containing an E3 ligase ligand (HY-112078) and a PROTAC linker. (S,R,S)-AHPC-Me-C2-piperazine can be used in the PROTAC SARS-CoV-2 Mpro degrader-8 (HY-181870) .
TSO-13 is the inhibitor for the main cysteine protease of Trypanosoma cruziCruzipain with an IC50 of 2.2 μM. TSO-13 inhibits T. cruzi in Vero cell with an IC50 of 1.9 μM .
Simeprevir (Standard) is the analytical standard of Simeprevir (HY-10241). This product is intended for research and analytical applications. Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
SR-A-174 is a SARS-CoV-2M Pro inhibitor with an IC50 of 0.060 μM. SR-A-174 has limited cell permeability and exhibits low activity in cells expressing M Pro-eGFP, with a cellular IC50 > 10 μM. SR-A-174 can be used in COVID-19-related research .
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 mainprotease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM .
PROTAC SARS-CoV-2 Mpro degrader-6 is a PROTACs degrader targeting the SARS-CoV-2mainprotease (M pro). PROTAC SARS-CoV-2 Mpro degrader-6 effectively induces the degradation of M pro and increases K48-linked polyubiquitination of M pro in HEK293 cells. PROTAC SARS-CoV-2 Mpro degrader-6 can be used in studies related to coronavirus disease 2019 (COVID-19) .
SARS-CoV-2 Mpro-IN-52 (compound 47) is a potent SARS-CoV-2 mainprotease (MPro) inhibitor (EC50 = 0.0099 µM) with antiviral activity. SARS-CoV-2 Mpro-IN-52 exhibits potent and broad-spectrum activity against MERS, OC43, 229E with EC50s of 0.00961, 0.138, and 0.117 µM. SARS-CoV-2 Mpro-IN-52 can be used for COVID-19 research .
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 mainprotease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .
SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 mainprotease (M pro) inhibitor, with an IC50 of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M pro and MERS-CoV M pro with IC50s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .
SARS-CoV-2 Mpro-IN-44 (Compound 25) is a broad-spectrum coronavirus mainprotease (Mpro) inhibitor. SARS-CoV-2 Mpro-IN-44 has inhibitory activity against a variety of high-risk coronaviruses (including SARS-CoV-2 and PEDV, etc.) (IC50: < 0.6 μM). SARS-CoV-2 Mpro-IN-44 achieves broad-spectrum inhibition of coronaviruses by enhancing the interaction with the conserved sites of Mpro. SARS-CoV-2 Mpro-IN-44 can be used for anti-coronavirus drug development .
Tirilazad (U 74006F free base) Standard is the analytical standard of Tirilazad (HY-132280). This product is intended for research and analytical applications. Tirilazad (U 74006F free base) is a neuroprotective agent. Tirilazad can also bind tightly to the mainprotease of the COVID-19 virus and exert anti-SARS-CoV-2 activity. Tirilazad scavenges hydroxyl and lipid peroxyl free radicals and maintains the levels of endogenous antioxidants. Tirilazad reduces cerebral infarct volume and improves neurobehavioral scores in animal models of focal ischemia. Tirilazad can be used in research related to ischemic stroke and subarachnoid hemorrhage .
GK730 is a potent and selective SARS-CoV-2 mainprotease inhibitor with an IC50 of 5.75 nM. GK730 does not inhibit cathepsin B, while exhibits weak inhibition of cathepsin L (IC50 = 11 μM). GK730 can simultaneously block the replication of the virus and the entry pathways for variants such as Omicron into cells. GK730 demonstrates an EC50 value of 5.70 μM against a wild-type SARS-CoV-2 strain in Vero E6 cells and CC50 value greater than 100 μM. GK730 can be used for the research of COVID-19 .
(Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the mainprotease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages .
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 mainprotease (M pro), with an IC50 of 24 nM for wild-type SARS-CoV-2 M pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .
SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus mainprotease (Mpro) inhibitor (IC50: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research .
PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the mainprotease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
Efonidipine (NZ-105) hydrochloride is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride inhibits SARS-CoV-2 mainprotease. Efonidipine hydrochloride modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 mainprotease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the mainprotease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC50=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882)；Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)) .
Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 mainprotease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC50 values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.
Arcapillin is a flavonoid that can be isolated from Artemisia capillaris Thunb. Arcapillin induces dose-dependent relaxation of ileum and pulmonary artery smooth muscle, causes slight urinary bladder smooth muscle contraction at highest tested concentrations. Arcapillin binds to the active site of SARS-CoV-2 Mpro via interactions with Gln139, His163, and His164, exhibits antiviral activity against SARS-CoV-2 and MERS-CoV. Arcapillin can be used for the research of gastrointestinal disorders, COVID-19, and Middle East respiratory syndrome (MERS) .
Efonidipine (NZ-105) hydrochloride monoethanolate (Standard) is the analytical standard of Efonidipine hydrochloride monoethanolate (HY-12502AR). This product is intended for research and analytical applications. Efonidipine (NZ-105) hydrochloride monoethanolate is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine hydrochloride monoethanolate inhibits SARS-CoV-2 mainprotease. Efonidipine hydrochloride monoethanolate modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine hydrochloride monoethanolate reduces plasma aldosterone levels in vivo. Efonidipine hydrochloride monoethanolate improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine hydrochloride monoethanolate can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis .
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 Mpro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .
TKB272 is an orally active and selective antiviral agent targeting the mainprotease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .
Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 mainprotease inhibitor with an IC50 of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .
PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs) .
UCI-1 is a SARS-CoV-2 mainprotease (M pro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting M pro. UCI-1 can be used in the study of anti-COVID-19 drugs .
TLP-3, Temporin L (HY-P2523) analogue, is a SARS-CoV-2mainprotease (Mpro) inhibitor with an IC50 of 7.0 μM. TLP-3 inhibits protease activity through stabilizing hydrogen bonding and hydrophobic interactions with key enzyme residues. TLP-3 can be used for the research of ARS-CoV‑2 infection .
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M pro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity .
Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 mainprotease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoVmainprotease (Mpro) .
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 Mpro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .
Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoV mainprotease (Mpro) .
Leupeptin (hemisulfate) (Standard) is the analytical standard of Leupeptin (hemisulfate). This product is intended for research and analytical applications. Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the mainprotease of SARS-CoV-2) and also has anti-inflammatory activity[1][2][3].
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2mainprotease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
Euptox A (9-Oxo-10, 11-dehydroageraphorone), a cadenine sesquiterpene, is the main toxin that can be isolated from Eupatorium adenophorum. Euptox A induces apoptosis by improving the gene expression level of apoptotic proteases such as caspase-10 in HeLa cells .
Arcapillin is a flavonoid that can be isolated from Artemisia capillaris Thunb. Arcapillin induces dose-dependent relaxation of ileum and pulmonary artery smooth muscle, causes slight urinary bladder smooth muscle contraction at highest tested concentrations. Arcapillin binds to the active site of SARS-CoV-2 Mpro via interactions with Gln139, His163, and His164, exhibits antiviral activity against SARS-CoV-2 and MERS-CoV. Arcapillin can be used for the research of gastrointestinal disorders, COVID-19, and Middle East respiratory syndrome (MERS) .
(±)-Alliin (Standard) is the analytical standard of (±)-Alliin. This product is intended for research and analytical applications. (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the mainprotease of SARS-CoV-2 (Mpro) .
Koenine is a carbazole alkaloid. It is predicted that Koenine has strong binding affinity and inhibitory ability to SARS-CoV-2mainprotease (M pro), which can be used in the research of anti-novel coronavirus drugs .
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The mainprotease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
Artecanin is a SARS-CoV-2 mainprotease (M pro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of M pro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with M pro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19 .
(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC50 values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.
SARS-CoV-2 3CLpro/3C-like protease Protein (His-Avi) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by E. coli, with N-His, N-Avi labeled tag.
SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by Sf9 insect cells, with N-His labeled tag.
SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His-Avi) is the recombinant Virus-derived SARS-CoV-2 3CLpro/3C-like protease protein, expressed by Sf9 insect cells, with N-His, N-Avi labeled tag.
Simeprevir- 13C,d3 is the 13C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the mainprotease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
